Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Pacira BioSciences (NASDAQ:PCRX) released its earnings results on Thursday. The company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01), FiscalAI reports. The company had revenue of $177.38 million for the quarter, compared to analyst estimates of $173.53 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $0.65 earnings per share.

Here are the key takeaways from Pacira BioSciences’ conference call:

• EXPAREL is showing renewed momentum with Q1 net sales of $143.3M (volume ~+7% YoY), expanded reimbursement outside the surgical bundle to >110 million covered lives, a new product-specific J-code, and strengthened IP protection with 21 Orange Book-listed patents.
• PCRX-201 (HCAd gene therapy for knee OA) is on a catalyst-rich path — Part A top-line (safety-focused) due later this year and Part B ~90-patient enrollment planned mid-year — but efficacy is early-stage and the program remains high-risk/high-reward.
• Early-intervention portfolio traction — Zilretta sales rose ~15% in Q1 with Phase III shoulder OA enrollment complete (top-line later this year), and iovera sales rose ~21% with a registrational spasticity readout expected by year-end.
• Management reiterated full-year 2026 guidance (total revenues $745–$770M, EXPAREL sales $600–$620M), reported strong adjusted EBITDA (~$40.2M in Q1), ended the quarter with $202M cash, and executed another $50M share repurchase (≈9M shares retired to date), supporting capital-return and financial flexibility.
• Near-term headwinds include revenue pressure from vial-mix shifts and GPO-driven discounting, Q1 shipping/return disruptions from winter storms, elevated SG&A tied to proxy activities, and policy uncertainty as the NOPAIN Act is currently set to expire in 2027.

Pacira BioSciences Price Performance

NASDAQ:PCRX traded up $0.35 during trading hours on Thursday, hitting $25.49. The company’s stock had a trading volume of 1,086,622 shares, compared to its average volume of 463,085. The stock has a fifty day simple moving average of $23.31 and a 200-day simple moving average of $23.14. The company has a market capitalization of $1.00 billion, a P/E ratio of 169.93 and a beta of 0.19. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28. Pacira BioSciences has a twelve month low of $18.80 and a twelve month high of $27.64.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Finally, Barclays reduced their price objective on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $30.25.

Insider Activity at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the sale, the insider directly owned 223,640 shares of the company’s stock, valued at approximately $5,103,464.80. This trade represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the sale, the senior vice president directly owned 52,313 shares in the company, valued at $1,088,633.53. The trade was a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 32,261 shares of company stock valued at $785,850 over the last ninety days. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Pacira BioSciences

A number of hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its stake in shares of Pacira BioSciences by 0.5% during the third quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company’s stock valued at $55,751,000 after purchasing an additional 11,831 shares in the last quarter. Balyasny Asset Management L.P. boosted its stake in shares of Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock valued at $50,925,000 after purchasing an additional 565,288 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after purchasing an additional 367,869 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Pacira BioSciences by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 676,352 shares of the company’s stock valued at $17,504,000 after purchasing an additional 49,079 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Pacira BioSciences by 7.9% during the third quarter. Invesco Ltd. now owns 517,424 shares of the company’s stock valued at $13,334,000 after purchasing an additional 38,025 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.